Table 2.
SHI annual expenditure for pharmacologically-treated patients with diabetes, 2010
| Total cost (€ billions) | ||
|---|---|---|
|
Screening |
0.03 |
|
|
Treatment/prevention of complications |
2.5 |
|
| Glycemic control |
1.7 |
|
| Screening of complications |
0.1 |
|
| Prevention of cardiovascular complications |
0.8 |
|
|
Treatment of diabetes-related complications |
4.2 |
|
| Cardiovascular |
0.8 |
|
| Renal insufficiency |
0.7 |
|
| Neuropathy |
0.3 |
|
| Vision loss |
0.1 |
|
| Other complications |
0.3 |
|
|
Health expenditure indirectly related to diabetes* |
3.6 |
|
|
Health expenditure unrelated to diabetes** |
7.4 |
|
| Total health expenditure for patients with treated diabetes | 17.7 | |
*Expenditure related to pathologies frequently found in patients with diabetes (e.g., certain cancers, obesity).
**Expenditure for patients with diabetes a priori unrelated to diabetes, including the share of the cost of complications not attribuk to diabetes, as well as other health expenditures for these patients that are not diabetes-related.
Source: CNAMTS [41].